Estimates of use increased from 16.6 percent in low-income countries to 65.0 percent in high-income countries<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Aug. 24, 2023 (HealthDay News) — Aspirin is underused in secondary prevention of cardiovascular disease (CVD), according to a study published online Aug. 22 in the Journal of the American Medical Association<\/em>.<\/p>\n Sang Gune K. Yoo, M.D., from Washington University in St. Louis, and colleagues reported and assessed aspirin use for secondary prevention of CVD in a cross-sectional analysis using data from 51 low-, middle-, and high-income countries. The overall pooled sample included 124,505 individuals aged 40 to 69 years.<\/p>\n The researchers found that 8.1 percent of the sample had a self-reported history of CVD. Aspirin use for secondary prevention among individuals with a history of CVD was 40.3 percent in the overall pooled sample. By income group, the estimates were 16.6, 24.5, 51.1, and 65.0 percent in low-, lower-middle, upper-middle, and high-income countries, respectively.<\/p>\n “In order to create interventions, we have to understand what is actually going on, which is what we’re trying to establish in this study,” Yoo said in a statement. “Then we can start to think about how to develop strategies to increase evidence-based aspirin use in order to save lives.”<\/p>\n Two authors disclosed ties to the pharmaceutical industry; one author reported that their employer has a patent and license, and a second author reported having a patent pending.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n